A mechanically-enforced, preset-volume dosing instrument for oral and enteral liquid medication — the one delivery route precision liquid handling never reached.
A parent at 2am, or a nurse mid-shift, reads a number, finds a marking on a plain graduated syringe, and visually judges where to stop. No mechanism intervenes. Repeated washing degrades the printed markings. Clinical guidance has spent thirty years improving the markings — never removing the judgment call.
Labs settled this argument decades ago with the pipette: select a volume, and a mechanism — not an eye — controls it. No lab tolerates visually judging a stopping point for a measured reagent. That standard never crossed into oral and enteral medication, where the person measuring is a tired parent or a busy nurse rather than a technician.
Both paths deliver the same claim: the dose becomes a mechanically controlled action rather than a manually judged position.
| Market | Size | CAGR | Relevance |
|---|---|---|---|
| Enteral syringes (global) | $0.38B–$1.6B+ in 2024–25 — a 4x spread across analysts | 5.2%–6.5% | The incumbent disposable this displaces or attaches to |
| Oral syringes (global) | Projected ~$1.37B by 2034 | 6.21% | Adjacent framing of the same device fleet |
| ENFit syringes | $298.9M in 2025 → $458.4M by 2032 | 6.3% | Standard-mandated segment; 1–10mL is ~60% of it |
| Precision oral/enteral dosing instruments | No analyst coverage — category does not exist | — | The white space this company is built to create |
ENFit is an industry-led safety standard (ISO 80369-3), not a federal mandate — voluntary, FDA-recognized, and legislated only in California, which has required non-Luer-compatible enteral connectors in health facilities since 2016. Adoption has been broad regardless. The tailwind is real but it's competitive momentum, not law: hospitals are already retraining staff and re-specifying oral/enteral syringes, so switching friction is unusually low right now.
The ENFit connector's volume displacement at small doses drew objections from neonatal clinicians, who called the accuracy at sub-2mL volumes unacceptable for NICU use; industry responded with a separate low-dose tip design, and the debate continues. So the standard conversion created a precision gap in exactly the segment named as the beachhead on slide 06 — doses measured in tenths of a millilitre for the smallest patients. Verify the current state of this before pitching; if it holds, it is the single strongest "why now" available.
Click-dial injector pens and mechanical dose-stops are established, commercially successful, and patent-protected. The market has already paid to replace visual judgment with mechanical certainty — just never on this route.
An MIT-affiliated team built a precision medication dispenser that handled viscous pediatric formulations at low volumes and outperformed both standard oral syringes and commercial dispensers in bench testing. It was never commercialized. The physics question is answered; the product question is not.
Home enteral feeding and home-administered pediatric therapy continue to grow, pushing more measured doses onto untrained caregivers in uncontrolled conditions — exactly the population the current device serves worst.
Error reduction is a hard sell: it asks a hospital to admit an error rate, and it prices a device against a harm that mostly stays invisible. Standard-of-care framing inverts that — it asks whether measuring a paediatric dose by eye is still defensible practice. Nanodropper is the closest working example: an adaptor that reduced eyedrop volume, published randomised trial data against standard of care, and moved from studies into clinic partnerships including Mayo Clinic and thousands of clinic locations. The company reported partnerships with Mayo Clinic, Southern College of Optometry and Keplr Vision by its third year, with adaptors available in every state across 2,000+ clinic locations. Trial data first, named institutions second, category language third.
Direct to pediatric pharmacy directors and patient-safety officers, then GPO and IDN contracts. Long cycles, but a single win converts a whole system's fleet.
Published human-factors data showing error reduction against real caregiver conditions. In this category, a peer-reviewed accuracy study is the marketing asset. Nursing and pediatric society channels carry it.
Medical distributors already stocking ENFit devices; specialty and DME channels for home enteral patients; retail pharmacy last, once institutional validation exists.
Deliberate sequencing: clinical credibility is the moat, and it can only be earned institution-first. A consumer-first launch would be cheaper and would forfeit the one asset a needle-shaped incumbent can't buy quickly.
A defined problem with published incidence data. A defined mechanism with commercial precedent on adjacent routes. Two candidate architectures with articulated trade-offs. And — newly identified — a granted US patent covering the closest prior attempt, which reframes the entire defensibility question below.
No prototype. No filed IP. No freedom-to-operate opinion. No human-factors data. No clinical or pharmacy design partner. No regulatory classification determination. No bottom-up market model. No revenue.
"Method and apparatus for precise measurement and dispensing of liquids." Inventors Ramadi, Srinivasan, Kantareddy, Hanumara and Nkwate — the same MIT-affiliated team behind the 2018 paper. Priority date May 2017.
Independent claim 1 requires a cap with a port coupled to a container, a second port, an air reservoir, and a detachable dispenser. Adjustable volume control appears only as a dependent claim — it reads on devices that already have that cap-and-reservoir architecture. This is a lay reading of the claim set, not an opinion.
Path A is a dose-stop on an existing syringe; Path B is a handheld instrument with a disposable tip. Neither couples a cap to a bottle or uses an air reservoir. That is encouraging, not clearance. Note also a related family publication (US20210275399A1) — continuation claims can differ materially from the parent.
Nothing in the source material describes the founding team. This is the single most common reason an incubator passes at this stage, and it cannot be inferred or drafted on your behalf. Below is the shape of what belongs here.
Name, role, and the one credential that makes this the right person for a regulated device with a hospital procurement cycle.
Who has built a precision mechanical device before, and what shipped. If unfilled, say so — a named gap reads better than a vague one.
A pediatric pharmacist, nurse, or device-regulatory advisor. Even an advisory relationship is worth more here than a blank.
| Instrument | Built for | Serves oral/enteral dosing? |
|---|---|---|
| Click-dial injector pens | Self-injection (insulin, peptides) | No — needle interface, different route |
| Plunger dose-stop attachments | Clinical micro-dosing | No — built around needle-based syringes |
| Dial-a-dose oral syringe (retail) | Home oral dosing | Partial — four fixed presets, no fine increment |
| Precision low-waste attachments | Dermal fillers, viscous clinical fluids | No — different route and viscosity regime |
| Academic precision dispenser (2018) | Pediatric oral dosing | Proved feasible — patented (US11903904B2), never commercialized |
| Standard graduated oral syringe | Current standard of care | This is the status quo, and the real competitor |
| This company | Oral/enteral liquid dosing, clinic and home | Open — subject to FTO against the above |
The competitor to beat is not another device. It is a plain syringe that costs cents and that every nurse and parent already knows how to use. Barriers to entry cut both ways: the incumbent's price is a moat against you, and clinical validation plus IP is the moat you build against a large device manufacturer copying the idea. Note that the differentiation claim here is now architectural — the closest granted patent claims a bottle-cap dispenser, not a syringe attachment or a handheld instrument — rather than the broader and no longer defensible claim that nothing in this space is patented.
Fabricated five-year revenue curves are the fastest way to lose a technical reviewer at this stage. What follows is the assumption set the projection must be built on — fill these in and the numbers build themselves.
Instrument COGS at 1k / 10k / 100k volume. Disposable tip COGS and attach rate. Instrument price against a cents-per-unit incumbent. Gross margin split between durable core and consumable.
Instruments per pediatric bed. Replacement cycle. Sales cycle length per hospital system. Systems converted per year. Home units per discharge program.
Regulatory path cost and duration (classification determines almost everything downstream). Tooling and first-article manufacturing. Human-factors study cost. IP prosecution.
Year 1–2: none — development. Year 3+: instrument sales, then recurring consumable revenue overtaking hardware. State when recurring exceeds durable; that crossover is the whole investment case.
The honest ask at this stage is a small, milestone-bounded round that buys the four answers determining whether this is fundable at all. Amounts below are an illustrative structure — set the number against real quotes before presenting.
A formal read of the granted claims against both architectures, plus the related family publication and any live continuations. Path A and Path B both appear to sit outside independent claim 1, but "appears to" is not an opinion and this patent runs to 2040. If it blocks Path B, the whole architecture choice changes. Cheapest possible way to avoid building the wrong thing.
One conversation, three possible outcomes: why it never commercialised (the diligence question), whether the patent is licensable, and whether any of them would advise or co-found. They hold a granted patent and no company — an unusual and time-limited opening. This also directly addresses the team gap on slide 10.
Both architectures to functional bench stage, then human factors under real caregiver conditions. Per slide 06, the trial is the marketing asset, not a checkbox — scope it early and pick a clinical endpoint, not a usability score.
Classification and predicate search specific to the oral/enteral category — distinct from the injectable predicates already identified — plus a costed case for hospital procurement.
This deck is an opportunity thesis. Freedom-to-operate, patentability, engineering feasibility, human factors, clinical procurement, regulatory pathway, and commercial strategy require formal development and validation before capital commitment. Market figures are third-party analyst estimates that vary materially by definition and should be independently verified and attributed before use.